Drug Patents owned by Amylyx

1. List of Relyvrio drug patents

RELYVRIO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857162 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(10 years from now)

US10251896 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(10 years from now)

US9872865 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(10 years from now)

US11071742 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(10 years from now)

US11583542 AMYLYX NA
Jul, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2027

Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient

NCE-1 date: 2026-09-29

Market Authorisation Date: 29 September, 2022

Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage

RELYVRIO family patents

9

United States

5

Korea, Republic of

4

Australia

4

Japan

3

China

2

European Union

1

Portugal

1

Slovenia

1

Croatia

1

ME

1

Hungary

1

Hong Kong

1

Poland

1

RS

1

Denmark

1

Canada

1

Lithuania

1

Spain

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in